{'fraction_non_alphanumeric': 0.012534818941504178, 'fraction_numerical': 0.001392757660167131, 'mean_word_length': 6.19, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Therapeutic monitoring of immunosuppressive drugs in pediatric patients: special considerations

The classical pharmacokinetic approach of therapeutic drug monitoring (TDM) is based on the measurement of drug concentrations in biological fluids to assess whether they correlate with the patients’ clinical condition and whether dosage or dosage intervals need to be changed. Very recently, the Immunosuppressive Drug Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology has classified TDM as multidisciplinary clinical specialty aimed at improving patient care by individually adjusting the dose of a drug [1]. TDM of an immunosuppressive drug is reasonable when